JP7543278B2 - 有機化合物 - Google Patents

有機化合物 Download PDF

Info

Publication number
JP7543278B2
JP7543278B2 JP2021539428A JP2021539428A JP7543278B2 JP 7543278 B2 JP7543278 B2 JP 7543278B2 JP 2021539428 A JP2021539428 A JP 2021539428A JP 2021539428 A JP2021539428 A JP 2021539428A JP 7543278 B2 JP7543278 B2 JP 7543278B2
Authority
JP
Japan
Prior art keywords
tumor
pde1
inhibitor
related disorder
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021539428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522942A5 (cg-RX-API-DMAC10.html
JP2022522942A (ja
Inventor
スナイダー，グレッチェン
ピー ウェノグル，ローレンス
オブライエン，ジェニファー
ヘンドリック，ジョゼフ
デイビス，ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of JP2022522942A publication Critical patent/JP2022522942A/ja
Publication of JP2022522942A5 publication Critical patent/JP2022522942A5/ja
Priority to JP2024139639A priority Critical patent/JP7856707B2/ja
Application granted granted Critical
Publication of JP7543278B2 publication Critical patent/JP7543278B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021539428A 2019-01-07 2020-01-07 有機化合物 Active JP7543278B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024139639A JP7856707B2 (ja) 2019-01-07 2024-08-21 有機化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789499P 2019-01-07 2019-01-07
US62/789,499 2019-01-07
PCT/US2020/012578 WO2020146384A1 (en) 2019-01-07 2020-01-07 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024139639A Division JP7856707B2 (ja) 2019-01-07 2024-08-21 有機化合物

Publications (3)

Publication Number Publication Date
JP2022522942A JP2022522942A (ja) 2022-04-21
JP2022522942A5 JP2022522942A5 (cg-RX-API-DMAC10.html) 2022-12-19
JP7543278B2 true JP7543278B2 (ja) 2024-09-02

Family

ID=71520889

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539428A Active JP7543278B2 (ja) 2019-01-07 2020-01-07 有機化合物
JP2024139639A Active JP7856707B2 (ja) 2019-01-07 2024-08-21 有機化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024139639A Active JP7856707B2 (ja) 2019-01-07 2024-08-21 有機化合物

Country Status (4)

Country Link
US (2) US12396992B2 (cg-RX-API-DMAC10.html)
EP (1) EP3908285A4 (cg-RX-API-DMAC10.html)
JP (2) JP7543278B2 (cg-RX-API-DMAC10.html)
WO (1) WO2020146384A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2020146384A1 (en) * 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US12599603B2 (en) 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease
MX2024010993A (es) * 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690935A (en) 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
EP2939676A1 (en) 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
EA201170769A1 (ru) 2008-12-06 2012-02-28 Интра-Селлулар Терапиз, Инк. Органические соединения
AU2009322903A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
WO2012177263A1 (en) 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
JP6224597B2 (ja) 2011-09-27 2017-11-01 バイオメッド バレー ディスカバリーズ，インコーポレイティド グリオーマを処置するための組成物及び方法
WO2013138118A1 (en) 2012-03-14 2013-09-19 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
US9499562B2 (en) 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
ES2717688T3 (es) 2013-03-15 2019-06-24 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
JP6696904B2 (ja) * 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
US10849862B2 (en) 2014-12-26 2020-12-01 Theravalues Corporation Formulation of curcumin and anti-PD-1 antibody
EP3288980B1 (en) * 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
MA46716A (fr) 2016-11-03 2019-09-11 Juno Therapeutics Inc Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
CA3047579A1 (en) 2016-12-22 2018-06-28 Abbvie Inc. Compositions and methods of enhancing or augmenting type i ifn production
AU2018325445A1 (en) 2017-08-31 2020-03-19 Abbvie Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
EP3856191A4 (en) 2018-09-25 2022-06-22 Intra-Cellular Therapies, Inc. NOVEL USES
WO2020146384A1 (en) * 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US12599603B2 (en) 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment
MX2024010993A (es) 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Eur. J. Med. Chem.，2018年，Vol. 150, pp. 742-756
Mol. Nutr. Food Res.，2011年，Vol. 55, No. 11, pp. 1677-1689

Also Published As

Publication number Publication date
EP3908285A1 (en) 2021-11-17
US20220072003A1 (en) 2022-03-10
US12396992B2 (en) 2025-08-26
JP2022522942A (ja) 2022-04-21
EP3908285A4 (en) 2022-10-19
JP2024164126A (ja) 2024-11-26
JP7856707B2 (ja) 2026-05-11
US20250339438A1 (en) 2025-11-06
WO2020146384A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
JP7856707B2 (ja) 有機化合物
US20250186446A1 (en) Organic compounds
EP3697767B1 (en) Compounds and methods for treating cancer
JP7631319B2 (ja) 治療方法
JP7493460B2 (ja) 有機化合物
RU2822394C1 (ru) Способы лечения
CN118922191A (zh) 有机化合物
HK40112650A (en) Organic compounds
RU2811918C2 (ru) Способы лечения раковых заболеваний и опухолей с использованием ингибиторов pde1
HK40066948A (en) Methods of treatment
HK40122851A (en) Organic compounds
HK40031775B (en) Compounds and methods for treating cancer
HK40031775A (en) Compounds and methods for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240821

R150 Certificate of patent or registration of utility model

Ref document number: 7543278

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150